Back to Agenda
Session 9 Plenary: Embracing AI: Practical Approaches to Transforming Clinical, Regulatory Affairs, and Post-Approval Activities
Session Chair(s)
Marcia Sam
Senior Manager, Regulatory Affairs
Regeneron Canada Company, Canada
Sabrina Ramkellawan
President and Board Director
Clinical Research Association of Canada, Canada
Artificial Intelligence (AI) is a tool that is becoming more prominent in the pharmaceutical industry. As pharmaceutical professionals, it is important for us to understand AI and how it can help us across our different roles. This session will investigate how adopting and embracing AI in our respective fields of expertise in clinical, regulatory affairs, safety and medical affairs will transform our work. Through sharing real experiences in AI use, participants will learn how AI can be beneficial to our respective roles.
- Leveraging AI in Clinical Development: Accelerating Study Design and Simplification
Katrina Mateo, Regeneron - AI Powered Translation for Global Pharma
Anand Sudhakar Tamilarasan, ATJP Consulting Services - AI in Action: Transforming Clinical Data Disclosure and Transparency
Anaya Rehman, Certara
Learning Objective : At the conclusion of this session, participants should be able to:- Identify how AI can enhance clinical trial design and accelerate drug development timelines
- Recognize AI tools and how they are being used in the pharmaceutical industry and future trends
- Mitigate some of the common risks associated with AI and AI tools
Speaker(s)
Leveraging AI in Clinical Development: Accelerating Study Design and Simplification
Katrina Mateo, PhD, MPH
Regeneron, United States
Associate Director, Development Innovation
AI Powered Translation for Global Pharma
Anand Sudhakar Tamilarasan
ATJP Consulting Services, United States
VP, Digital Transformation Leader
AI in Action: Transforming Clinical Data Disclosure and Transparency
Anaya Rehman, MD, MS
Certara, Canada
Senior Transparency Specialist
Have an account?